A.S. ANKUDINOV, A.N. KALYAGIN

Irkutsk Medical State University, Irkutsk

 Contact details:

Ankudinov A.S. — PhD (medicine), Associate Professor of the Department of Simulation Technologies and Emergency Medical Care

Address: 1 Krasnogo Vosstaniya St., Irkutsk, Russian Federation, 664003, tel.: +7 (3952) 24-38-25, e-mail: andruhin.box@ya.ru

 The purpose — to analyze the frequency of anemia and decreased glomerular filtration rate (GFR) in patients with chronic heart failure (CHF) and rheumatoid arthritis (RA) and to identify the possible associations of these indicators with the systemic inflammation parameters and the CHF course.

Material and methods. The main group consisted of 134 patients with CHF and RA, the comparison group — of 122 patients without RA. The functional class (FC) of CHF was identified according to NYHAI-II. The diagnosis of RA was made on the basis of radiological and serological studies. The radiological stage of RA was I-III according to Steinbrocker. The basic anti-inflammatory drug for RA was methotrexate. A comparative analysis of clinical and laboratory parameters was carried out for patients of both groups, as well as a possible association of hemoglobin levels and GFR with RA activity indicators and CHF severity parameters. The processing was carried out using the STATISTICA 10.0 program. The critical level of significance when testing statistical hypotheses was p < 0.05.

Results. Statistically significant differences in the frequency of anemia and a decrease in GFR were revealed between the examined groups. In the group of patients with CHF and RA, direct statistically significant associations of hemoglobin and GFR levels with LVL were revealed, as well as statistically significant associations of hemoglobin and GFR levels with NT-proBNP levels and DAS28 values.

Conclusion. Statistically significant associations between the studied parameters were observed in patients with CHF and RA against the background of systemic inflammation, which may negatively affect the course of CHF.

Key words: chronic heart failure, rheumatoid arthritis, comorbidity, systemic inflammation, anemia, glomerular filtration rate.

REFERENCES

1. Kruger K., Nublein H. Cardiovascular comorbidities in rheumatoid arthritis. Zeitschrift fur Rheumatologie, 2019, vol. 78 (3), pp. 221–227. DOI: 10.1007/s00393-018-0584-5
2. Tarlovskaya E.I. Comorbidity and polymorbidity — modern interpretation and urgent tasks facing the therapeutic community. Kardiologiya, 2018, vol. 58 (9S), pp. 29–38 (in Russ.). DOI: 10.18087/cardio.2562
3. Chaulin A.M., Grigor’eva Yu.V., Duplyakov D.V. Comorbidity of chronic obstructive pulmonary disease and cardiovascular diseases: common factors, pathophysiological mechanisms and clinical significance. Klinicheskaya praktika, 2020, vol. 11 (1), pp. 38–47 (in Russ.). DOI:10.17816/clinpract21218
4. Drapkina O.M. Results of the ESC Congress. European clinical guidelines what’s new? Rossiyskiy kardiologicheskiy zhurnal, 2021, vol. 26 (3S), pp. 46–84 (in Russ.). DOI: 10.15829/1560-4071-2021-4684
5. Shepel’ R.N., Drapkina O.M. Angiogenesis in patients with chronic heart failure: focus on vascular endothelial growth factor, pentraxin-3 and transforming growth factor beta. Ratsional’naya farmakoterapiya v kardiologii, 2020, vol. 16 (3), pp. 439–448. DOI: 10.20996/1819-6446-2020-05-02
6. Glezeva N., Baugh J.A. Role of inflammation in the pathogenesis of heart failure with preserve dejection fraction an ditspotential as a therapeutic target. Heart Failure Reviews, 2014, vol. 19 (5), pp. 681–694. DOI: 10.1007/s10741-013-9405-8
7. Tkachenko T.I., Borovkova N.Yu., Buyanova M.V. Anemia in chronic heart failure: a look at the pathogenesis and ways of correction. Doktor Ru, 2019, vol. 2 (157), pp. 31–36 (in Russ.). DOI: 10.31550/1727-2378-2019-157-2-31-36
8. Izilyaeva E.A., Ekimov V.V. Changes in the structural and functional state of the myocardium in patients with chronic kidney disease and chronic heart failure. Izvestiya Rossiyskoy voenno-meditsinskoy akademii, 2019, vol. 3 (S1), pp. 78–81 (in Russ.).
9. Clinical guidelines: chronic heart failure. Rossiyskoe kardiologicheskoe obshchestvo. Natsional’noe obshchestvo po izucheniyu serdechnoy nedostatochnosti i zabolevaniy miokarda, 2020 (accessed on: 27.12.2021), avaialble at: http://cr.rosminzdrav.ru/schema/156
10. Mc Donagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, vol. 42 (36), rr. 3599‒3726. DOI: 10.1093/eurheartj/ehab368
11. Nasonov E.L. Revmatologiya: klinicheskie rekomendatsii [Rheumatology: clinical guidelines]. Moscow: GEOTAR-Media, 2017. 464 p.
12. Singh J.A., Saag K.G., Bridges S.L. et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis and Rheumatology, 2016, vol. 68 (1), pp. 1‒26. DOI: 10.1002/art.39480
13. Rebrova O.Yu. Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA [Statistical analysis of medical data. Application of the application package STATISTICA]. Moscow: Media Sfera, 2002. 312 p.
14. Zhang Y., Bauersachs J., Langer H.F. Immune mechanisms in heart failure. European Journal Heart Failure, 2017, vol. 19 (11), pp. 1379‒1389. DOI: 10.1002/ejhf.942
15. Paolillo S., Scardovi A.B., Campodonico J. Role of comorbidities in heart failure prognosis Part I: anaemia, iron deficiency, diabetes, atrial fibrillation. European Journal of Preventive Cardiology, 2020, vol. 27, pp. 27‒34. DOI: 10.1177/2047487320960288
16. Von Haehling S., Anker M.S., Jankowska E.A., Ponikowski P., Anker SD. Anemia in chronic heart failure: can we treat? What to treat? Heart Failure Review, 2012, vol. 17 (2), pp. 203–210, avaialble at: https://pubmed.ncbi.nlm.nih.gov/21979835/ DOI: 10.1007/s10741-011-9283-x
17. Mullens W., Damman K., Testani J.M., Martens P., Mueller C., Coats A. et al. Evaluation of kidney function throughout the heart failure trajectory — a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, vol. 22 (4), pp. 584–603, available at: https://pubmed.ncbi.nlm.nih.gov/31908120/ DOI: 10.1002/ejhf.1697
18. Agca R., Heslinga S.C., Rollefstad M., Heslinga I.B., McInnes M.J. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders. Annals of the Rheumatic Diseases, 2017, vol. 76 (1), pp. 17–28, available at: https://pubmed.ncbi.nlm.nih.gov/27697765/ DOI: 10.1136/annrheumdis-2016-209775.